Prevents type sits at the center of this dementia and brain health question.
A single 14-day course of intravenous infusions can now delay the onset of clinical type 1 diabetes by roughly two years in children and adults identified as high risk — and in some cases, it has kept the disease at bay for six years or longer. The drug is teplizumab-mzwv, sold under the brand name Tzield, and it became the first and only FDA-approved disease-modifying therapy for type 1 diabetes when it received approval on November 17, 2022. Unlike insulin, which manages the disease after it arrives, teplizumab works upstream: it deactivates the rogue immune cells that destroy the pancreas’s insulin-producing beta cells, essentially putting the brakes on an autoimmune attack already in progress. For readers of this site, the relevance may not be immediately obvious — but the connection between type 1 diabetes and brain health is well established.
Poorly managed blood sugar accelerates cognitive decline, increases dementia risk, and damages the small blood vessels that feed the brain. A treatment that delays or prevents diabetes onset in a child is, by extension, a treatment that protects decades of neurological health. Consider a five-year-old who screens positive for two autoantibodies and would otherwise develop insulin-dependent diabetes by age seven. If teplizumab pushes that diagnosis to age nine or beyond, those are years of stable blood sugar during a critical window of brain development. This article covers how teplizumab works, what the clinical trial data actually shows, the recent push to expand its use to children as young as one year old, the staggering cost and how families navigate it, and what screening looks like for families who may not even know their child is at risk.
Table of Contents
- How Does the Injection That Prevents Type 1 Diabetes Work in High-Risk Children?
- What the Clinical Trials Reveal About Teplizumab’s Effectiveness — and Its Limits
- Expanding the Age Range — Teplizumab for Toddlers and Young Children
- How Families Can Find Out If Their Child Is at Risk — and What Screening Involves
- The Cost Problem — $200,000 for a 14-Day Treatment
- The Brain Health Connection — Why Diabetes Prevention Matters for Cognitive Aging
- What Comes Next — The Road Ahead for Type 1 Diabetes Prevention
- Conclusion
- Frequently Asked Questions
How Does the Injection That Prevents Type 1 Diabetes Work in High-Risk Children?
Type 1 diabetes is an autoimmune disease, not a lifestyle disease. The body’s own T cells — a class of immune cell normally tasked with fighting infections — misidentify insulin-producing beta cells in the pancreas as threats and methodically destroy them. By the time a child shows symptoms like excessive thirst, weight loss, and fatigue, roughly 80 to 90 percent of their beta cells are already gone. Teplizumab is a humanized anti-CD3 monoclonal antibody, which means it binds to a specific protein on the surface of T cells and effectively deactivates the ones responsible for the autoimmune attack. It does not suppress the entire immune system the way older immunosuppressive drugs do — it targets the autoreactive T cells driving the destruction. The treatment is administered as a single 14-day course of daily intravenous infusions with escalating doses. There is no pill form and no at-home option; the child or adult receives the infusions in a clinical setting over two weeks, and then the course is complete. In the original TrialNet TN-10 study, this single course was enough to produce a measurable delay in disease progression over years of follow-up.
That is a remarkable feature of the therapy — it is not a daily medication but a one-time intervention that alters the immune trajectory. However, it is not a cure. It slows the process; it does not stop it permanently in most patients. Researchers are still studying whether a second course might extend the benefit further. To put this in practical terms, compare teplizumab to the only other option currently available for a child in stage 2 type 1 diabetes: watchful waiting. Before Tzield’s approval, families who learned their child had multiple autoantibodies and abnormal glucose tolerance were told to monitor blood sugar and prepare for an eventual diabetes diagnosis. There was no intervention to offer. Teplizumab changed that equation — it gave clinicians something to actually do during the window between immune activation and clinical disease.
What the Clinical Trials Reveal About Teplizumab’s Effectiveness — and Its Limits
The pivotal data behind teplizumab’s approval came from the TrialNet TN-10 study, a randomized, placebo-controlled trial of relatives of people with type 1 diabetes who had at least two autoantibodies and abnormal glucose tolerance. Over a median follow-up of 51 months, 43 percent of patients in the teplizumab group progressed to stage 3 (clinical) type 1 diabetes, compared with 72 percent in the placebo group. The median time to diagnosis was 48.4 months for teplizumab versus 24.4 months for placebo — a difference of roughly two years. The hazard ratio was 0.41, with a p-value of 0.006, meaning the result was statistically robust and not a fluke of small sample size. Longer follow-up made the picture even more encouraging. At six years, 50 percent of teplizumab patients remained diabetes-free, compared with only 22 percent of those who received placebo. The median time to diagnosis in the treatment group extended to 59.6 months versus 27.1 months in the placebo group.
These numbers matter because every additional year without diabetes is a year without the burden of insulin injections, continuous glucose monitoring, carbohydrate counting, and the acute risks of hypoglycemia and diabetic ketoacidosis — the latter being a potentially life-threatening emergency that is disproportionately dangerous in young children. However, there are important caveats. The TN-10 trial was small — only 76 participants total. And the drug did not prevent diabetes outright in most patients; it delayed it. About half of the treated group still progressed to clinical disease within six years. For families, this means teplizumab buys time — sometimes a lot of time — but it is not a guarantee. Additionally, the Phase 3 PROTECT trial, which studied 328 patients who already had stage 3 type 1 diabetes, found that teplizumab preserved beta-cell function: at week 78, 94.9 percent of treated patients maintained clinically meaningful C-peptide levels compared with 79.2 percent on placebo. This suggests the drug has value even after diagnosis, but the primary approved indication remains for stage 2, pre-clinical disease.
Expanding the Age Range — Teplizumab for Toddlers and Young Children
The current fda approval covers adults and children aged eight years and older, but type 1 diabetes frequently strikes much younger. Many children develop clinical disease between ages two and six, which means the existing approval misses a significant portion of the population most likely to benefit. That is why Sanofi, which acquired original developer Provention Bio in 2023, submitted a supplemental Biologics License Application to expand Tzield’s indication down to children as young as one year old. On January 5, 2026, the FDA accepted this application for Priority Review, with a target action date of April 29, 2026. The data supporting this expansion comes from the PETITE-T1D trial, a Phase 4 study of 23 children under age eight with stage 2 type 1 diabetes. The mean age of participants was 4.8 years, with the youngest just 1.7 years old. At the interim one-year analysis, 90 percent of children remained free of progression to stage 3 — only 2 of the 23 participants developed clinical diabetes.
The estimated probability of remaining diabetes-free was 0.90, with a 95 percent confidence interval of 0.64 to 0.97. These results were presented at the International Society for Pediatric and Adolescent Diabetes conference in Montréal in November 2025 and subsequently published in Diabetologia. The safety data from PETITE-T1D was largely reassuring. All 23 participants experienced at least one adverse event, which sounds alarming but is typical for immunomodulatory therapies administered over 14 days — most events were mild to moderate. Crucially, there were no grade 4 or grade 5 adverse events, meaning no life-threatening reactions and no deaths. Three participants, or 13 percent, discontinued treatment due to anemia, elevated liver enzymes, or rash. For a toddler, even a mild infusion reaction requires careful monitoring, and families should understand that the 14-day infusion course is not trivial — it demands significant time in a clinical setting and close follow-up. But the absence of severe safety signals in this very young cohort is a meaningful data point.
How Families Can Find Out If Their Child Is at Risk — and What Screening Involves
Most children who develop type 1 diabetes have no family history of the disease. That said, the current pathway to teplizumab treatment requires a confirmed diagnosis of stage 2 type 1 diabetes, which means a child needs to be screened before symptoms ever appear. Screening involves testing for autoantibodies — specifically, antibodies against insulin, glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), and zinc transporter 8 (ZnT8). A child with two or more confirmed autoantibodies plus abnormal glucose tolerance is classified as stage 2 and is a candidate for teplizumab. The American Diabetes Association’s 2026 Standards of Care formalize this staging system and screening guidance. The TEDDY study, one of the largest longitudinal studies of type 1 diabetes risk, found that 21 percent of 363 children with at least one autoantibody by age three went on to develop clinical diabetes. Children with multiple autoantibodies face a nearly 100 percent lifetime risk of progressing to clinical disease.
This is not a soft probability — it is essentially a certainty. The question is not whether the child will develop diabetes, but when. That is exactly the window where teplizumab can intervene. The tradeoff with population-wide screening is cost and infrastructure. Autoantibody testing requires a blood draw, and the follow-up oral glucose tolerance test is a two-hour procedure that is particularly difficult with toddlers. Programs like TrialNet offer free autoantibody screening for relatives of people with type 1 diabetes, and some states and countries have begun pilot programs for general population screening. But most pediatricians do not routinely screen for type 1 diabetes autoantibodies, which means many children who could benefit from teplizumab are never identified until they present in diabetic ketoacidosis — a dangerous and sometimes fatal emergency that remains the first sign of disease for roughly 30 to 40 percent of newly diagnosed children.
The Cost Problem — $200,000 for a 14-Day Treatment
Teplizumab’s clinical promise runs headlong into a practical barrier: as of January 2026, the wholesale price is approximately $14,411 per vial, and a full 14-day course costs roughly $201,753. Some patients require additional vials based on body weight, which can push the cost higher. When the drug launched in 2022, the price was around $194,000 per course, so it has already increased. For a therapy aimed at children — many of whom are covered by their parents’ insurance or by Medicaid — this cost raises serious access and equity concerns. Sanofi does offer a copay assistance program for commercially insured patients that can potentially reduce out-of-pocket costs to zero. But copay assistance does not address the underlying list price, and it does not help uninsured families or those on government insurance programs that prohibit copay cards. Moreover, insurers must agree to cover the drug in the first place, and coverage decisions for a relatively new, expensive biologic are inconsistent.
Some families have reported months-long prior authorization battles. The economic argument in favor of coverage is straightforward — lifetime costs of managing type 1 diabetes, including insulin, devices, emergency care, and long-term complications, easily exceed $200,000 and often reach several times that amount. But insurers operate on shorter time horizons, and the upfront cost of teplizumab remains a significant barrier. There is also a philosophical tension worth acknowledging. Teplizumab delays diabetes; in many cases, it does not prevent it permanently. Paying $200,000 to delay a disease by two to six years is a different value proposition than paying $200,000 to prevent it entirely. For families and for the healthcare system, the calculus depends heavily on how long the delay lasts and whether future treatments — including possible second courses of teplizumab or combination therapies — can extend the benefit further. These are open questions that the research community is actively investigating.
The Brain Health Connection — Why Diabetes Prevention Matters for Cognitive Aging
For readers focused on dementia and brain health, the link between type 1 diabetes and neurological risk deserves specific attention. Chronic hyperglycemia damages blood vessels throughout the body, including the microvasculature of the brain. Over decades, this vascular damage contributes to white matter lesions, reduced cerebral blood flow, and accelerated brain atrophy. Studies have shown that people with type 1 diabetes diagnosed in childhood have measurable differences in brain structure and cognitive performance by early adulthood, including slower processing speed and reduced executive function.
Preventing or delaying diabetes onset during childhood may preserve brain health during the very years when neural architecture is being established. Severe hypoglycemia — a recurring risk for anyone on insulin therapy — also carries neurological consequences. Repeated episodes of dangerously low blood sugar have been associated with increased dementia risk later in life. A child who avoids insulin dependence for an additional two to six years avoids not only the burden of daily management but also the cumulative neurological toll of blood sugar volatility during a critical developmental period. This is not a speculative connection; it is grounded in decades of epidemiological and imaging data.
What Comes Next — The Road Ahead for Type 1 Diabetes Prevention
The FDA’s decision on expanding teplizumab to children as young as one year old, expected by April 29, 2026, will be a landmark moment regardless of the outcome. Approval would open the door to treating toddlers identified through early screening, potentially intervening years before the disease would otherwise manifest. It would also intensify the conversation around population-level autoantibody screening — because a treatment is only useful if you can identify the children who need it.
Beyond the age expansion, researchers are exploring whether combination therapies — teplizumab paired with other immunomodulatory agents — might produce longer or even permanent delays. There is also interest in whether repeat courses of teplizumab could extend the benefit for patients who received the initial 14-day infusion. The field of type 1 diabetes prevention has moved from theoretical to practical in a remarkably short time, and teplizumab is the proof of concept that disease modification is possible. For families, for clinicians, and for the broader brain health community, the message is clear: screening matters, early intervention works, and the window to act is before symptoms appear — not after.
Conclusion
Teplizumab represents a genuine inflection point in the management of type 1 diabetes. For the first time, there is an FDA-approved treatment that can delay the onset of clinical disease in high-risk individuals, buying years of life without the burden of insulin dependence. The clinical data — a 50 percent diabetes-free rate at six years versus 22 percent with placebo — is compelling, and the expansion of the indication to children as young as one could dramatically broaden the population that benefits. For anyone concerned about long-term brain health, the downstream implications of preventing or delaying childhood diabetes are significant, from reduced vascular damage to fewer episodes of dangerous hypoglycemia during critical years of neurodevelopment.
The barriers are real: a price tag exceeding $200,000, inconsistent insurance coverage, and the fact that most at-risk children are never screened in the first place. But the trajectory is unmistakably positive. As screening programs expand, as cost negotiations evolve, and as researchers explore combination strategies to extend the benefit, teplizumab is likely to become a cornerstone of pediatric preventive medicine. Families with a history of type 1 diabetes should discuss autoantibody screening with their pediatrician or connect with programs like TrialNet that offer free testing. The time to act is before symptoms appear.
Frequently Asked Questions
What is teplizumab and how is it different from insulin?
Teplizumab (brand name Tzield) is a monoclonal antibody that modifies the immune system’s attack on insulin-producing beta cells. It is given as a one-time, 14-day intravenous infusion course to delay the onset of type 1 diabetes. Insulin, by contrast, is a hormone replacement therapy used after beta cells have been destroyed — it manages the disease but does not alter its progression.
Who is eligible for teplizumab treatment?
Currently, teplizumab is FDA-approved for adults and children aged 8 and older who have been diagnosed with stage 2 type 1 diabetes — meaning they have two or more diabetes-related autoantibodies and abnormal glucose tolerance but have not yet developed clinical symptoms. A decision on expanding eligibility to children as young as 1 year old is expected by April 29, 2026.
How much does teplizumab cost, and is it covered by insurance?
The wholesale cost of a full 14-day course is approximately $201,753 as of January 2026. A copay assistance program from Sanofi can reduce out-of-pocket costs to $0 for commercially insured patients, but coverage varies by insurer and prior authorization may be required.
Does teplizumab cure type 1 diabetes?
No. Teplizumab delays the onset of clinical type 1 diabetes but does not cure it. In the pivotal trial, the median delay was about two years, and at six years, 50 percent of treated patients remained diabetes-free. However, many patients eventually progress to clinical disease. Researchers are studying whether additional courses or combination therapies could extend the benefit.
How is a child identified as high risk for type 1 diabetes?
Through autoantibody screening — a blood test that checks for antibodies against insulin, GAD, IA-2, and ZnT8. Children with two or more confirmed autoantibodies plus abnormal results on an oral glucose tolerance test are classified as stage 2 type 1 diabetes. Programs like TrialNet offer free screening for relatives of people with type 1 diabetes.
What are the side effects of teplizumab in young children?
In the PETITE-T1D trial of children under age 8, all participants experienced at least one adverse event, but most were mild to moderate. There were no life-threatening or fatal adverse events. Three of 23 participants (13%) discontinued treatment due to anemia, elevated liver enzymes, or rash.
You Might Also Like
- This Drug for Type 2 Diabetes Also Reverses Heart Failure
- The Drug That Treats Both Type 1 and Type 2 Diabetes Differently
- The Immunotherapy That Works Best Combined With Chemotherapy
For more, see National Institute on Aging.
